Quantum Diagnostics Sdn Bhd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Quantum Diagnostics Sdn Bhd - overview
Established
2011
Location
Petaling Jaya, Selangor, Malaysia
Primary Industry
Healthcare
About
Based in Malaysia, Quantum Diagnostics Sdn Bhd specializes in medical diagnostic services, offering a variety of laboratory tests and advanced technologies to enhance patient care through accurate and timely results. Quantum Diagnostics Sdn Bhd, founded in 2011 in Petaling Jaya, Malaysia, operates as a medical diagnostics provider. The company was acquired by TPG in September 2018, acquiring a 100% stake from LabAsia Sdn Bhd. The founder's background is not detailed, and the company has completed one funding deal.
Quantum Diagnostics is a prominent provider of medical diagnostic services in Malaysia, focusing on a diverse range of laboratory tests and advanced diagnostic technologies. The company’s core offerings include Non-invasive Prenatal Testing (NiPT) for genetic abnormalities and liver health assessments through tests such as FibroTest, ActiTest, and SteatoTest. These tests are designed to provide accurate results to healthcare providers, facilitating informed decisions regarding patient care. Quantum Diagnostics serves a wide array of clients, including hospitals, clinics, and individual patients, extending its reach beyond Malaysia into various international markets.
The company emphasizes quality assurance and innovative technology to meet the growing demand for reliable medical diagnostics. In 2023, Quantum Diagnostics reported a revenue of USD 1. 43 mn and an EBITDA of USD 979,366. The company generates revenue through direct service provision to healthcare facilities and individual consumers, offering a comprehensive service catalogue that includes various diagnostic panels and tests.
The pricing structure is designed to be competitive within the medical diagnostics sector, ensuring access to critical testing for both healthcare institutions and individual patients. Quantum Diagnostics plans to enhance its product offerings with new diagnostic tests and technologies aimed at addressing emerging healthcare needs. The company aims to expand into new markets, targeting regions within Southeast Asia by the end of 2025. Recent funding from TPG will support these initiatives, focusing on product development and market penetration.
The acquisition in September 2018 has poised the company for strategic growth, allowing it to leverage new resources and expertise.
Current Investors
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories
Website
www.quantumdxs.com
Verticals
HealthTech
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Quantum Diagnostics Sdn Bhd - financials
| Fiscal Year Ended | Sep 30, 2011 | Sep 30, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 876,776 | 8,139,141 | 15,037,165 | 19,137,190 | 23,674,800 | 26,333,646 | 31,673,602 | 37,050,396 | 18,169,835 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | 27.3% | 23.7% | 11.2% | 20.3% | 17.0% | (51.0%) | - | - | - |
| EBITDA (USD) | (3,595) | (798,545) | (4,549,602) | 218,361 | 847,460 | 169,382 | 1,930,057 | 7,305,681 | 7,788,867 | (851,676) | - | - | - |
| Operating Income (USD) | (3,595) | (868,425) | (4,901,408) | (153,415) | 325,046 | (619,761) | 1,293,397 | 6,724,294 | 4,165,699 | (4,605,226) | - | - | - |
| Operating Margin | - | (99.0%) | (60.2%) | (1.0%) | 1.7% | (2.6%) | 4.9% | 21.2% | 11.2% | (25.3%) | - | - | - |
| % EBITDA Margin | - | (91.1%) | (55.9%) | 1.5% | 4.4% | 0.7% | 7.3% | 23.1% | 21.0% | (4.7%) | - | - | - |
| NET Income (USD) | (3,595) | (868,425) | (4,901,408) | (197,638) | 241,765 | (753,865) | 1,115,195 | 6,297,933 | 780,849 | (16,005,728) | - | - | - |
| % Net Margin | - | (99.0%) | (60.2%) | (1.3%) | 1.3% | (3.2%) | 4.2% | 19.9% | 2.1% | (88.1%) | - | - | - |
Quantum Diagnostics Sdn Bhd - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Quantum Diagnostics Sdn Bhd | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.